Navigation Links
Anesthesiologists Use Caldolor® To Provide Preemptive Pain Control for Surgical Patients at U.S. Medical Centers
Date:3/2/2011

e, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable ibuprofen treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit www.cumberlandpharma.com.

Important Note Regarding Forward-Looking and External Statements

This press release contains forward-looking statements that reflect Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of operations are subject to influences outside of the Company's control. Risk factors that could materially affect results of operations include, among others, those factors discussed in Cumberland's Annual Report on Form 10-K as filed with the SEC on March 19, 2010. There can be no assurance that results or developments anticipated by Cumberland will be realized or, even if realized, that they will have the expected effects. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cu
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
2. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
3. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
4. Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
5. Caldolor® (ibuprofen) Injection Gaining Approval on Formulary at U.S. Medical Centers
6. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
7. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
8. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... 12 Crux Biomedical® was named one of "50 Companies to ... survey, conducted by Medical Device and Diagnostics Industry (MD+DI), was published in ... to identify firms that have either achieved success or have the potential ... , , ...
... , BELOIT, Wis. , July 12 Sheffield ... and excipient products for the biotech and pharmaceutical markets, has been ... , , ... Award recognizes Sheffield Bio-Sciences, consistent execution of quality and services for ...
Cached Medicine Technology:Crux Biomedical Named One of Top 50 Companies to Watch 2Sheffield Bio-Science Wins 2010 Lilly Global Supplier Award 2
(Date:10/22/2014)... Isabel Healthcare will participate in ... Conference on October 22-24 in Las Vegas, NV. Jason ... panel discussion on Technology in Health Professions Education – ... diagnostic decision support tool and clinical education platform designed ... and clinical learners. The Isabel tools help clinicians broaden ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... panels and format for its “OneMedForum 2009” ... 2009, in San Francisco at the Sir ... “drivers and disrupters” affecting each of the ... Nervous System and Neurostimulation; Cardiology; Urology and ...
... Inc.,(OTC Bulletin Board: USFM), a diversified commercial Farming ... (OTCFN), a division of,National Financial Communications Corp. (NFC), ... OTCFN Report details US Farms, Inc.,s current operations,industry ... and,management team. Interested parties can download the ...
... MEETING, Pa., Dec. 4 Genaera Corporation (Nasdaq: ... of Genaera, is scheduled to present at the 2008 RBC ... RBC Capital Markets, panel discussion of obesity, entitled, "Shrinking The ... Square Hotel in New York on Wednesday, December 11 at ...
... from bone marrow may serve as a novel therapeutic option ... characterized by extraordinarily fragile skin, according to a study pre-published ... American Society of Hematology. , , ... fragile skin and blistering on touch, akin to third degree ...
... in Giving as Demand for Nonprofit Services Peaks , ... than half of Coloradans report that they will give the ... economic downturn, according to " Generous Colorado: Why Donors Give ... data from surveys conducted October 2008. With demand for services ...
... purchasing the Green Bracelet at www.simmonsjewelryco.com , ... Empowerment Fund (D.E.F.), Hearst Magazines, and A Diamond is ... Africa" dinner held at Hearst Tower in Manhattan Monday evening ... Simmons and special guests including Tamsin Smith , ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: